Inada Y, Itoh K, Kamiya K, Sugihara H, Nishikawa K
Biology Laboratories, Takeda Chemical Industries, Ltd., Osaka, Japan.
Jpn J Pharmacol. 1988 Jun;47(2):135-41. doi: 10.1254/jjp.47.135.
The synthetic design and the biological activities of structurally new angiotensin converting enzyme (ACE) inhibitors, (R)-3-amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepine-5-acetic acid derivatives, are described. A number of compounds in this series showed potent ACE inhibitory activity in vitro and in vivo. Structure-activity studies indicated that a piperidyl moiety on the amino group at the 3-position in this series conferred long-lasting ACE inhibitory activity and that the duration of activity depended on the length of the carbon chain in the 1-carboxy-omega-(4-piperidyl)alkyl group. (R)-3-[(S)-1-carboxy-5-(4-piperidyl)-pentyl]amino-4-oxo-2,3,4,5-tetrahydro- 1,5-benzothiazepine-5-acetic acid (CV-5975) was selected as the most promising ACE inhibitor for further studies because of its marked inhibitory activity.
本文描述了结构新颖的血管紧张素转换酶(ACE)抑制剂,即(R)-3-氨基-4-氧代-2,3,4,5-四氢-1,5-苯并硫氮杂䓬-5-乙酸衍生物的合成设计及其生物活性。该系列中的许多化合物在体外和体内均表现出强效的ACE抑制活性。构效关系研究表明,该系列中3位氨基上的哌啶基部分赋予了持久的ACE抑制活性,且活性持续时间取决于1-羧基-ω-(4-哌啶基)烷基中碳链的长度。(R)-3-[(S)-1-羧基-5-(4-哌啶基)-戊基]氨基-4-氧代-2,3,4,5-四氢-1,5-苯并硫氮杂䓬-5-乙酸(CV-5975)因其显著的抑制活性而被选为最具前景的ACE抑制剂用于进一步研究。